<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163192">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01994096</url>
  </required_header>
  <id_info>
    <org_study_id>NL41676.042.12</org_study_id>
    <nct_id>NCT01994096</nct_id>
  </id_info>
  <brief_title>Optimal Dosage of Caspofungin in Critically Ill Patients</brief_title>
  <official_title>Pharmacokinetics and Optimal Dosage of Caspofungin in Critically Ill Patients With Suspected Invasive Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Groningen</source>
  <oversight_info>
    <authority>The Netherlands: the Central Committee on Research Involving Human Subjects (CCMO)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intensive care unit (ICU) patients are especially at risk for invasive candidiasis due to
      the presence of risk factors. It is known that in critically ill patients, alterations in
      function of various organs and body systems can influence the pharmacokinetics and hence the
      plasma concentration of a drug. A study of caspofungin in ICU patients has found a high
      inter- and intra-individual variability in caspofungin concentration. Factors that caused
      subtherapeutic caspofungin plasma concentrations were body weight &gt; 75 kg and
      hypoalbuminemia. Furthermore, an efficacy study showed a lower response rate for caspofungin
      among patients with a higher disease severity score.

      As a result of the altered pharmacokinetics, under- or over-exposure of caspofungin can
      occur in critically ill patients and an adjusted dosage might be necessary in these
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The optimal dosage of caspofungin in relation to adequate exposure (measured as AUC) in critically ill patients.</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of caspofungin in critically ill patients.</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of pharmacokinetic parameters and the plasma concentration of caspofungin with disease severity scores.</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the plasma concentration of caspofungin with candida eradication.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the plasma concentration of caspofungin with inflammation parameters.</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC/MIC ratio and highest observed plasma concentration (Cmax)/MIC ratio.</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constructing a pharmacokinetic model of caspofungin in critically ill patients.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-related adverse events of caspofungin.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Critically Ill</condition>
  <condition>Suspected Invasive Candidiasis</condition>
  <arm_group>
    <arm_group_label>Caspofungin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 arm, dose adjustment of caspofungin when exposure is inadequate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofungin</intervention_name>
    <arm_group_label>Caspofungin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment with caspofungin.

          -  Admission to an ICU.

          -  Age â‰¥ 18 years.

          -  Suspected invasive candidiasis, established by the physician.

        Exclusion Criteria:

          -  Blood sampling by central venous catheter or peripheral cannula not possible.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
    <phone>0031503614070</phone>
    <email>j.w.c.alffenaar@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
      <phone>0031503614070</phone>
      <email>j.w.c.alffenaar@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>November 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Groningen</investigator_affiliation>
    <investigator_full_name>JWC Alffenaar</investigator_full_name>
    <investigator_title>PharmD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
